These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 26645957)

  • 21. Placental Transfer of Dengue Virus (DENV)-Specific Antibodies and Kinetics of DENV Infection-Enhancing Activity in Brazilian Infants.
    Castanha PM; Braga C; Cordeiro MT; Souza AI; Silva CD; Martelli CM; van Panhuis WG; Nascimento EJ; Marques ET
    J Infect Dis; 2016 Jul; 214(2):265-72. PubMed ID: 27056951
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dengue Virus (DENV) Neutralizing Antibody Kinetics in Children After Symptomatic Primary and Postprimary DENV Infection.
    Clapham HE; Rodriguez-Barraquer I; Azman AS; Althouse BM; Salje H; Gibbons RV; Rothman AL; Jarman RG; Nisalak A; Thaisomboonsuk B; Kalayanarooj S; Nimmannitya S; Vaughn DW; Green S; Yoon IK; Cummings DA
    J Infect Dis; 2016 May; 213(9):1428-35. PubMed ID: 26704615
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Divergence of the dengue virus type 2 Cosmopolitan genotype associated with two predominant serotype shifts between 1 and 2 in Surabaya, Indonesia, 2008-2014.
    Kotaki T; Yamanaka A; Mulyatno KC; Churrotin S; Sucipto TH; Labiqah A; Ahwanah NL; Soegijanto S; Kameoka M; Konishi E
    Infect Genet Evol; 2016 Jan; 37():88-93. PubMed ID: 26553170
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Complement-independent dengue virus type 1 infection-enhancing antibody reduces complement-dependent and -independent neutralizing antibody activity.
    Yamanaka A; Konishi E
    Vaccine; 2016 Dec; 34(51):6449-6457. PubMed ID: 27866774
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epidemiology of Infant Dengue Cases Illuminates Serotype-Specificity in the Interaction between Immunity and Disease, and Changes in Transmission Dynamics.
    Clapham H; Cummings DA; Nisalak A; Kalayanarooj S; Thaisomboonsuk B; Klungthong C; Fernandez S; Srikiatkhachorn A; Macareo LR; Lessler J; Reiser J; Yoon IK
    PLoS Negl Trop Dis; 2015 Dec; 9(12):e0004262. PubMed ID: 26658730
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dengue virus infection-enhancing activity in serum samples with neutralizing activity as determined by using FcγR-expressing cells.
    Moi ML; Lim CK; Chua KB; Takasaki T; Kurane I
    PLoS Negl Trop Dis; 2012; 6(2):e1536. PubMed ID: 22389741
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dengue-Immune Humans Have Higher Levels of Complement-Independent Enhancing Antibody than Complement-Dependent Neutralizing Antibody.
    Yamanaka A; Konishi E
    Jpn J Infect Dis; 2017 Sep; 70(5):579-581. PubMed ID: 28367878
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serotype-specific and cross-reactive neutralizing antibody responses in cynomolgus monkeys after infection with multiple dengue virus serotypes.
    Ito M; Katakai Y; Ono F; Akari H; Mukai RZ; Takasaki T; Kotaki A; Kurane I
    Arch Virol; 2011 Jun; 156(6):1073-7. PubMed ID: 21409446
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A tetravalent recombinant dengue domain III protein vaccine stimulates neutralizing and enhancing antibodies in mice.
    Block OK; Rodrigo WW; Quinn M; Jin X; Rose RC; Schlesinger JJ
    Vaccine; 2010 Nov; 28(51):8085-94. PubMed ID: 20959154
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tests in mice of a dengue vaccine candidate made of chimeric Junin virus-like particles and conserved dengue virus envelope sequences.
    Mareze VA; Borio CS; Bilen MF; Fleith R; Mirazo S; Mansur DS; Arbiza J; Lozano ME; Bruña-Romero O
    Appl Microbiol Biotechnol; 2016 Jan; 100(1):125-33. PubMed ID: 26386688
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular characterization of dengue and chikungunya virus strains circulating in New Delhi, India.
    Afreen N; Deeba F; Khan WH; Haider SH; Kazim SN; Ishrat R; Naqvi IH; Shareef MY; Broor S; Ahmed A; Parveen S
    Microbiol Immunol; 2014 Dec; 58(12):688-96. PubMed ID: 25346397
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neutralizing antibody response variation against dengue 3 strains.
    Alvarez M; Pavon-Oro A; Rodriguez-Roche R; Bernardo L; Morier L; Sanchez L; Alvarez AM; Guzmán MG
    J Med Virol; 2008 Oct; 80(10):1783-9. PubMed ID: 18712848
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recombinant envelope protein-based enzyme immunoassay for IgG antibodies is comparable to neutralization tests for epidemiological studies of dengue infection.
    Rocha ES; Oliveira JG; Santos JR; Rodrigues GO; Figueiredo LB; Pessanha JE; Proietti FA; Fonseca FG; Bonjardim CA; Ferreira PC; Kroon EG
    J Virol Methods; 2013 Jan; 187(1):114-20. PubMed ID: 23018061
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties.
    Liu Y; Zhou J; Yu Z; Fang D; Fu C; Zhu X; He Z; Yan H; Jiang L
    BMC Microbiol; 2014 Dec; 14():233. PubMed ID: 25520151
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Investigation of dengue virus and yellow fever virus seropositivities in blood donors from Central/Northern Anatolia, Turkey].
    Ergünay K; Saygan MB; Aydoğan S; Litzba N; Niedrig M; Pınar A; Us D
    Mikrobiyol Bul; 2010 Jul; 44(3):415-24. PubMed ID: 21063991
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of Zika virus neutralizing antibodies in normal healthy Thais.
    Sornjai W; Jaratsittisin J; Auewarakul P; Wikan N; Smith DR
    Sci Rep; 2018 Nov; 8(1):17193. PubMed ID: 30464242
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular characterization of dengue viruses circulating during 2009-2012 in Uttar Pradesh, India.
    Mishra G; Jain A; Prakash O; Prakash S; Kumar R; Garg RK; Pandey N; Singh M
    J Med Virol; 2015 Jan; 87(1):68-75. PubMed ID: 24889214
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genomic analysis and growth characteristic of dengue viruses from Makassar, Indonesia.
    Sasmono RT; Wahid I; Trimarsanto H; Yohan B; Wahyuni S; Hertanto M; Yusuf I; Mubin H; Ganda IJ; Latief R; Bifani PJ; Shi PY; Schreiber MJ
    Infect Genet Evol; 2015 Jun; 32():165-77. PubMed ID: 25784569
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Replacement of pr gene with Japanese encephalitis virus pr using reverse genetics reduces antibody-dependent enhancement of dengue virus 2 infection.
    Wang Y; Si L; Luo Y; Guo X; Zhou J; Fang D; Yan H; Zeng G; Jiang L
    Appl Microbiol Biotechnol; 2015 Nov; 99(22):9685-98. PubMed ID: 26219500
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serological evidence for transmission of multiple dengue virus serotypes in Papua New Guinea and West Papua prior to 1963.
    Luang-Suarkia D; Ernst T; Alpers MP; Garruto R; Smith D; Imrie A
    PLoS Negl Trop Dis; 2017 Apr; 11(4):e0005488. PubMed ID: 28437465
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.